Down 75% From Its High, Has Novavax Stock Become Too Cheap to Pass Up?
Novavax (NASDAQ: NVAX) is facing some significant headwinds. Its financials aren't in great shape, and its future remains questionable. Investors have been dumping the stock in droves, and it is no longer near the highs it reached toward the start of the year. But with the stock trading at a deep discount to its rivals, has it become so cheap that it's worth taking a chance on Novavax?
Novavax trades at a price-to-sales multiple of well below 1. It's remarkably cheap when compared to fellow COVID-19 vaccine makers Pfizer and Moderna.
Source Fool.com
Novavax Inc. Aktie
10,54 €
1,39 %
Die Community bevorzugt leicht Novavax Inc. mit mehr Buy- als Sell-Einschätzungen.
Mit einem Kursziel von 22 € für Novavax Inc., würde dies eine mehr als zweifache Steigerung des aktuellen Kurses von 10.54 € bedeuten.
